Profile of certolizumab and its potential in the treatment of psoriatic arthritis

References

• Christophers E Psoriasis – epidemiology and clinical spectrum Clin Exp Dermatol 2001 26 4 314 320 11422182
   PubMed Web of Science ®Google Scholar
• Kane D Stafford L Bresnihan B FitzGerald O A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience Rheumatology (Oxford) 2003 42 12 1460 1468 14523223
   PubMed Web of Science ®Google Scholar
• Partsch G Steiner G Leeb BF Dunky A Broll H Smolen JS Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid J Rheumatol 1997 24 3 518 523 9058659
   PubMed Web of Science ®Google Scholar
• Gladman DD Brockbank J Psoriatic arthritis Expert Opin Investig Drugs 2000 9 7 1511 1522
   Web of Science ®Google Scholar
• Laloux L Voisin MC Allain J Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis Ann Rheum Dis 2001 60 4 316 321 11247858
   PubMed Web of Science ®Google Scholar
• Saad AA Ashcroft DM Watson KD Symmons DP Noyce PR Hyrich KL Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register Rheumatology (Oxford) 2010 49 4 697 705 20056769
   PubMed Web of Science ®Google Scholar
• Punzi L Podswiadek M Sfriso P Oliviero F Fiocco U Todesco S Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis Autoimmun Rev 2007 6 8 524 528 17854743
   PubMed Web of Science ®Google Scholar
• Strohal R Chimenti S Vena GA Girolomoni G Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence J Dermatolog Treat Epub November 10, 2012
   Web of Science ®Google Scholar
• van der Heijde D Kavanaugh A Gladman DD Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2 Arthritis Rheum 2007 56 8 2698 2707 17665424
   PubMed Web of Science ®Google Scholar
• Papoutsaki M Costanzo A Chimenti MS Chimenti S Adalimumab for the treatment of severe psoriasis and psoriatic arthritis Expert Opin Biol Ther 2008 8 3 363 370 18294106
   PubMed Web of Science ®Google Scholar
• Tracey D Klareskog L Sasso EH Salfeld JG Tak PP Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 2008 117 2 244 279 18155297
   PubMed Web of Science ®Google Scholar
• Ritchlin CT Kavanaugh A Gladman DD Treatment recommendations for psoriatic arthritis Ann Rheum Dis 2009 68 9 1387 1394 18952643
   PubMed Web of Science ®Google Scholar
• FitzGerald O McInnes I Spondyloarthropathy: disease at the crossroads of immunity Best Pract Res Clin Rheumatol 2006 20 5 949 967 16980217
   PubMed Web of Science ®Google Scholar
• Chimenti MS Ballanti E Perricone C Cipriani P Giacomelli R Perricone R Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways Aut Rev 2013 3 12 5 599 606
   PubMed Web of Science ®Google Scholar
• Hueber AJ McInnes IB Immune regulation in psoriasis and psoriatic arthritis-recent developments Immunol Lett 2007 114 2 59 65 17928070
   PubMed Web of Science ®Google Scholar
• Codullo V McInnes IB Synovial tissue response to treatment in psoriatic arthritis Open Rheumatol J 2011 5 133 137 22279513
   PubMedGoogle Scholar
• Gerhard N Krenn V Magalhães R Morawietz L Brändlein S König A IgVH-genes analysis from psoriatic arthritis shows involvement of antigen-activated synovial B-lymphocytes Z Rheumatol 2002 61 6 718 727 12491138
   PubMed Web of Science ®Google Scholar
• Cañete JD Santiago B Cantaert T Ectopic lymphoid neogenesis in psoriatic arthritis Ann Rheum Dis 2007 66 6 720 726 17223654
   PubMed Web of Science ®Google Scholar
• Valesini G Iannuccelli C Marocchi E Pascoli L Scalzi V Di Franco M Biological and clinical effects of anti-TNFalpha treatment Autoimmun Rev 2007 7 1 35 41 17967723
   PubMed Web of Science ®Google Scholar
• Baeten D Kruithof E Van den Bosch F Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study Arthritis Rheum 2001 44 1 186 195 11212159
   PubMed Web of Science ®Google Scholar
• Ohshima S Mima T Sasai M Tumour necrosis factor alpha (TNF-a) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF therapy for RA Cytokine 2000 12 3 281 288 10704256
   PubMed Web of Science ®Google Scholar
• Kruithof E Baeten D Van den Bosch F Mielants H Veys EM De Keyser F Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy Ann Rheum Dis 2005 64 4 529 536 15388510
   PubMed Web of Science ®Google Scholar
• Chimenti MS Perricone C Graceffa D Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment Clin Exp Rheumatol 2012 30 1 23 30 22260811
   PubMed Web of Science ®Google Scholar
• Gossec L Smolen JS Gaujoux-Viala C European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies Ann Rheum Dis 2012 71 1 4 12 21953336
   PubMed Web of Science ®Google Scholar
• Statkute L Ruderman EM Novel TNF antagonists for the treatment of rheumatoid arthritis Expert Opin Investig Drugs 2010 19 1 105 115
   PubMed Web of Science ®Google Scholar
• Choy EH Hazleman B Smith M Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial Rheumatology (Oxford) 2002 41 10 1133 1137 12364632
   PubMed Web of Science ®Google Scholar
• Harris JM Martin NE Modi M Pegylation: a novel process for modifying pharmacokinetics Clin Pharmacokinet 2001 40 7 539 551 11510630
   PubMed Web of Science ®Google Scholar
• Nesbitt A Fossati G Bergin M Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor agents Inflamm Bowel Dis 2007 13 11 1323 1332 17636564
   PubMed Web of Science ®Google Scholar
• Cominelli F Cytokine-based therapies for Crohn’s disease – new paradigms N Engl J Med 2004 351 20 2045 2048 15537904
   PubMed Web of Science ®Google Scholar
• Ueda N Tsukamoto H Mitoma H The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α Ann Rheum Dis 2012 71 Suppl 3 665
   Google Scholar
• Ohshima S Saeki Y Mima T Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy J Clin Immunol 1999 19 5 305 313 10535607
   PubMed Web of Science ®Google Scholar
• Taylor PC Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases Curr Opin Pharmacol 2010 10 3 308 315 20172761
   PubMed Web of Science ®Google Scholar
• Kirchner S Holler E Haffner S Andreesen R Eissner G Effect of different tumor necrosis factor (TNF) reactive agents on reverse signalling of membrane integrated TNF in monocytes Cytokine 2004 28 2 67 74 15381183
   PubMed Web of Science ®Google Scholar
• Watts AD Hunt NH Wanigasekara Y A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in ‘reverse signalling.’ EMBO J 1999 18 8 2119 2126 10205166
   PubMed Web of Science ®Google Scholar
• Harashima S Horiuchi T Hatta N Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells J Immunol 2001 166 1 130 136 11123285
   PubMed Web of Science ®Google Scholar
• Mitoma H Horiuchi T Hatta N Infliximab induces potent anti-inflammatory responses by outside-to- inside signals through transmembrane TNF-[alpha] Gastroenterology 2005 128 2 376 392 15685549
   PubMed Web of Science ®Google Scholar
• Eissner G Kolch W Scheurich P Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system Cytokine Growth Factor Rev 2004 15 5 353 366 15450251
   PubMed Web of Science ®Google Scholar
• van Lent PL Blom AB Grevers L Sloetjes A van den Berg WB Toll-like receptor 4 induced FcgR expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: Toll-like receptor 4 largely regulates FcgR expression by IL-10 Ann Rheum Dis 2007 66 3 334 340 17068066
   PubMed Web of Science ®Google Scholar
• Schreiber S Rutgeerts P Fedorak RN A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn‘s disease Gastroenterology 2005 129 3 807 818 Erratum in: Gastroenterology 2005;129(5):1808 16143120
   PubMed Web of Science ®Google Scholar
• Sandborn WJ Feagan BG Stoinov S Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1) Gastroenterology 2006 130 Suppl 2 A1 A912 16642574
   PubMedGoogle Scholar
• Kozuch PL Hanauer SB General principles and pharmacology of biologics in inflammatory bowel disease Gastroenterol Clin North Am 2006 35 4 757 773 17129812
   PubMed Web of Science ®Google Scholar
• Colombel J Sandborn WJ Rutgeerts P Adalimumab induces and maintains clinical response and remission in patients with active Crohn’s disease: results of the CHARM trial Gastroenterology 2006 130 Suppl 2 A1 A912 16642574
   PubMedGoogle Scholar
• Shen C Assche GV Colpaert S Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept Aliment Pharmacol Ther 2005 21 3 251 258 15691299
   PubMed Web of Science ®Google Scholar
• Jazayeri JA Carroll GJ Fc-based cytokines: prospects for engineering superior therapeutics Bio Drugs 2008 22 1 11 26
   Google Scholar
• Palframan R Airey M Moore A Vugler A Nesbitt A Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis J Immunol Methods 2009 348 1–2 36 41 19567252
   PubMed Web of Science ®Google Scholar
• Fleischmann R The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis Expert Opin Biol Ther 2010 10 5 773 786 20230188
   PubMed Web of Science ®Google Scholar
• Mease PJ Fleischmann RM Deodhar A Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID-PsA) Ann Rheum Dis 2012 71 Suppl 3 LB0001
   Google Scholar
• Sieper J Kivitz AJ Van Tubergen AM Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study Ann Rheum Disease 2012 64 Suppl10 558
   Google Scholar
• Deeks ED Certolizumab Pegol: A Review of Its Use in the Management of Rheumatoid Arthritis Drugs 2013 22 [Epub ahead of print]
   Google Scholar
• Furst DE Keystone EC Fleischmann R Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 Ann Rheum Dis 2010 69 Suppl 1 i2 29 Erratum in: Ann Rheum Dis 2011;70(8)1519 19995740
   PubMed Web of Science ®Google Scholar
• Furst DE Shaikh SA Greenwald M Evaluation of two dosing regimens of certolizumab pegol for maintenace of clinical response in patients with active rheumatoid arthritis: primary results from Doseflex, a Phase IIIB study Ann Rheum Dis 2012 71 Suppl3 SAT0126
   Google Scholar
• Fleischmann R Vencovsky J van Vollenhoven RF Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4 WARD study Ann Rheum Dis 2009 68 6 805 811 19015206
   PubMed Web of Science ®Google Scholar
• Ramiro S van Tubergen AM Landewé RB RAPID and FAST4 WARD trials: certolizumab pegol for rheumatoid arthritis Expert Rev Clin Immunol 2010 6 5 713 720 20828279
   PubMed Web of Science ®Google Scholar
• Van der Heijde D Maksymowych W Landewé R Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12 week magnetic resonance imaging results of a phase 3 double blind randomized placebo-controlled study Arthritis Rheum 2012 64 Suppl10 1705
   Google Scholar
• Sieper J Rudwaleit M Baraliakos X The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis Ann Rheum Dis 2009 68 Suppl 2 ii1 ii44 19433414
   PubMed Web of Science ®Google Scholar
• Reich K Ortonne JP Gottlieb AB Successful treatment of moderate to severe plaque psoriasis with the pegylated fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension Br J Dermatol 2012 167 1 180 190 22413944
   PubMed Web of Science ®Google Scholar
• Shu Q Amin MA Ruth JH Suppression of endothelial cell activity by inhibition of TNFα Arthritis Res Ther 2012 14 2 R88 22534470
   PubMed Web of Science ®Google Scholar
• Mease PJ Fleischmann RM Wollenhaupt J Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis with and without prior anti-TNF exposure: 24 week results of a phase 3 double-blind randomized placebo-controlled study Ann Rheum Dis 2012 71 Suppl 3 150 22039170
   PubMed Web of Science ®Google Scholar
• Gladman DD Fleischmann RM Coteur G Woltering F Mease P Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients: 24 week patient reported outcome results of a phase 3 double blind randomized placebo-controlled study Arthritis Rheum 2012 64 Suppl 10 557 21953497
   PubMed Web of Science ®Google Scholar